While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ORGANIZATION
ORGANIZATION
- Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
- JPMA Issues “Severe Warning” to MTPC for Violation of PAL Related to Medway Injection
November 1, 2013
- PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
- Keizai Doyukai Recommends Measures to Ensure Adequate Funding for Proposed Japanese NIH
October 31, 2013
- Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
- Medwatcher Japan Calls for Legislation to Regulate Clinical Research in Wake of Diovan Scandal
October 28, 2013
- JPMA to Consider Information Disclosure on Provision of Labor to Research Institutes in Response to Diovan Scandal
October 28, 2013
- JMA Vice Pres. Nakagawa to Be Reinstated as CSIMC Member
October 25, 2013
- No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
- JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
- JGA Tells Members to Use Unified Trade Name “Losarhyd” for Generic Version of Combination Drug Preminent
October 1, 2013
- Generic Share Increases to 26.6% on Volume Basis in April-June 2013: JGA
October 1, 2013
- JSGM to Propose Incentive Dispensing Fee for Pharmacies That Carry Cheaper Generics, Unification of Premiums for Generic Dispensing Systems
September 26, 2013
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…